MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) encodes MEK1 (also known as MAP2K1), a dual-specificity serine/threonine kinase that serves as a critical intermediate in the RAS-RAF-MEK-ERK (MAPK) signaling cascade. MEK1 phosphorylates and activates ERK1/2 (Extracellular Signal-Regulated Kinases), linking upstream RAF kinase signaling to downstream cellular responses including gene expression, cell proliferation, and synaptic plasticity[1].
In the central nervous system, MEK1-ERK signaling is essential for neuronal development, synaptic plasticity, long-term potentiation (LTP), learning, and memory formation. Dysregulated MEK-ERK signaling is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and various psychiatric disorders. Germline mutations in MAP2K1 cause Cardiofaciocutaneous Syndrome (CFC) and Noonan Syndrome, developmental disorders that highlight the critical importance of this kinase in normal growth and neural development[2].
| Property | Value |
|---|---|
| Gene Symbol | MAP2K1 |
| Full Name | Mitogen-Activated Protein Kinase Kinase 1 |
| Aliases | MEK1, MEK, PRKMK1 |
| Chromosomal Location | 15q22.31 |
| NCBI Gene ID | 5604 |
| Ensembl ID | ENSG00000169032 |
| UniProt ID | Q02750 |
| OMIM | 176872 |
| Gene Type | Protein coding |
| Property | Value |
|---|---|
| Protein Name | Dual specificity mitogen-activated protein kinase kinase 1 (MEK1) |
| Molecular Weight | 43 kDa |
| Amino Acids | 393 amino acids |
| Subcellular Localization | Cytoplasm, nucleus (upon activation) |
| Protein Family | MAP2K family (MAP kinases) |
| Catalytic Activity | Dual-specificity kinase ( phosphorylates Tyr and Thr) |
MEK1 possesses several functional domains essential for its enzymatic activity and regulation:
Key Structural Features:
During CNS development, MEK1-ERK signaling regulates[1:1]:
MEK-ERK signaling is a central mediator of activity-dependent synaptic plasticity[3]:
MEK1-ERK signaling promotes neuronal survival through:
The MEK-ERK signaling pathway is profoundly dysregulated in AD brains[4]:
Hyperactive ERK in AD:
Mechanisms of Dysregulation:
MEK-ERK pathway represents a therapeutic target in AD[5][6]:
| Approach | Agent | Status | Mechanism |
|---|---|---|---|
| MEK inhibition | Selumetinib | Preclinical | Reduce ERK hyperactivation |
| RAF inhibition | Sorafenib | Preclinical | Block upstream activation |
| ERK inhibition | FR180204 | Preclinical | Direct ERK blockade |
Challenges:
In AD, MEK-ERK interacts with:
MEK-ERK signaling is altered in PD pathogenesis[7]:
Changes in PD Brain:
Mechanisms:
MEK inhibitors show neuroprotective potential in PD models[8]:
Considerations:
Germline missense mutations in MAP2K1 cause CFC:
MAP2K1 is one of several genes causing Noonan Syndrome:
| Drug | Original Indication | CNS Potential | Challenges |
|---|---|---|---|
| Selumetinib | Cancer | Neuroprotection | CNS penetration |
| Trametinib | Cancer | Anti-inflammatory | Off-target effects |
| PD98059 | Research | Experimental | Limited solubility |
| Binimetinib | Cancer | Under study | Clinical trials needed |
Several trials explore MEK inhibition in neurodegeneration:
Growth Factors, neurotransmitters
↓
RAS (HRAS/NRAS/KRAS)
↓
RAF (ARAF/BRAF/CRAF)
↓
MEK1/2 (MAP2K1/MAP2K2)
↓
ERK1/2 (MAPK1/MAPK3)
↓
Gene Expression, Cell Growth,
Synaptic Plasticity, Survival
MAPK signaling in brain development and cognitive function. Nat Rev Neurosci. 2018. ↩︎ ↩︎
MEK function in neuronal physiology and pathogenesis. J Neurosci. 2011. ↩︎
MAPK signaling in synaptic plasticity and memory. Learn Mem. 2014. ↩︎
ERK/MAPK signaling in Alzheimer disease pathogenesis. Exp Neurobiol. 2015. ↩︎
Targeting MAPK pathways in AD and PD. Neurotherapeutics. 2016. ↩︎
MEK inhibitors in neurodegenerative disease. J Neurochem. 2016. ↩︎
MAP kinase signaling inParkinson disease. Exp Neurobiol. 2016. ↩︎
MEK inhibitors for neuroprotection in PD. Mov Disord. 2017. ↩︎